

# Proteomics and pancreatic cystic neoplasms: a pilot study

<b>Submission date</b> 03/06/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 10/06/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 10/06/2010	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Jean Louis Frossard

**Contact details**  
Service of Gastroenterology  
Dept of Internal Medicine  
Rue Micheli du Crest  
Geneva  
Switzerland  
1211

## Additional identifiers

**Protocol serial number**  
001

## Study information

**Scientific Title**  
Use of proteomics to differentiate between benign and potentially malignant pancreatic cystic neoplasms: a pilot study

**Study objectives**

We postulate that a proteomic analysis of pancreatic cystic fluid from patients having a pancreatic cystic neoplasms would be more performant than any other technique to discriminate between benign and malignant lesions.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Ethic Committee of Hirslanden Clinic (Surgery Section), Bern approved in March 2009

### **Study design**

Prospective cohort proteomic analysis study

### **Primary study design**

Observational

### **Study type(s)**

Diagnostic

### **Health condition(s) or problem(s) studied**

Pancreatic disease

### **Interventions**

Prospective collection of pancreatic cystic fluid in patients undergoing open pancreatic surgery aimed at removing the cystic neoplasms. Cystic fluid samples collected by direct puncture and submitted to proteomic analysis.

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome(s)**

To help find specific protein markers to better differentiate between benign and potentially malignant pancreatic cystic neoplasms

### **Key secondary outcome(s)**

To correlate results of the proteomic analysis to pancreatic histologic staining of surgical samples

### **Completion date**

31/12/2010

## **Eligibility**

### **Key inclusion criteria**

1. Patients with pancreatic cystic neoplasms as demonstrated by CT scan planned for open surgery
2. Each patient gave his/her informed consent before surgery

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Age < 18 years old
2. Pregnant women

**Date of first enrolment**

01/06/2009

**Date of final enrolment**

31/12/2010

**Locations****Countries of recruitment**

Switzerland

**Study participating centre****Service of Gastroenterology**

Geneva

Switzerland

1211

**Sponsor information****Organisation**

Geneva University Hospital (Switzerland)

**ROR**

<https://ror.org/01m1pv723>

**Funder(s)**

**Funder type**

Hospital/treatment centre

**Funder Name**

Geneva University Hospital (Switzerland)

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes